Limaprost is an orally-active antithrombotic and vasodilator structurally related to
alprostadil. Oral administration of limaprost causes a dose-dependent inhibition of platelet
aggregation, an increase in platelet CAMP and a mild suppression of platelet adhesiveness.
In patients with pulmonary emphysema, tuberculosis, and chronic lung disease, treatment
with limaprost reportedly produces significant cardiac improvements.
